Biomarin Pharmaceutical

Martin Shkreli, Chief Investment Officer of MSMB Capital Management

Portfolio

Pharmaceutical Companies Gird for Drug-Price Reckoning

October 8, 2015

Premium

Tourbillon Thrives on a Heady Mix of PR and Performance

June 9, 2015